Rossari Biotech Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹586Cr
- +17.7% YoY
- +7.7% QoQ
- Net profit
- ₹37Cr
- +5.7% YoY
- +8.8% QoQ
- Margin
- 12%
- −1 pp YoY
- 0 pp QoQ
Guidance rank: #45 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Revenue growth in Q2 FY26 was strong at 18% YoY, driven largely by volume increases across all verticals (HPPC, TSC, AHN). Rossari expects steady volume-driven revenue growth with exports rising robustly (36% YoY in Q2), supported by product portfolio expansion and new capacities.
From Rossari Biotech Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Revenue growth in Q2 FY26 was strong at 18% YoY, driven largely by volume increases across all verticals (HPPC, TSC, AHN).
- Exports grew robustly by 36% YoY in Q2 and 27% in H1, now comprising nearly 28% of total revenue, with growth driven by new geographies like Far East, Southeast Asia, and MENA.
- Capacity expansions (total planned Rs. 192 crore capex) including 20,000 MT at Dahej and 15,000 MT ethoxylation at Unitop will support future revenue growth.
- Capex projects expected to deliver 3-4x asset turns at full utilization, with peak utilization by FY28.
- Non-EO and new product portfolios (approx. 50 new products in pipeline) expected to ramp up gradually.
- Institutional and B2C verticals currently soft but losses are reducing; expected to scale meaningfully over time.
2 more points from Rossari Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rossari Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rs. 97 crore and Rs. 95 crore capex announced last quarter, expected to come on stream in FY27 via 5-6 projects in a phased manner.
- Capacity to reach approximately 385,000 tons by FY26 end.
- New ethoxylation capacity commissioned at Unitop (15,000 tons) and Dahej (20,000 tons) confirmed; part of ongoing expansions.
- Total planned capital outlay of Rs. 192 crore nearing completion; remaining projects to be commissioned in coming months.
- Board approved up to USD 8 million investment in wholly owned subsidiary in Saudi Arabia (Rossari International Limited Company) for feasibility and expansion studies.
- Small capex underway in Southeast Asia (Thailand) for a blending unit.
2 more points from Rossari Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rossari Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- There is mention of growing export momentum and revenue ramp-up expected every quarter, especially from non-EO business, depending on market conditions.
- The company is focusing on emerging geographies such as Far East, Southeast Asia, and MENA regions to sustain or increase export sales momentum.
- There is also ongoing capacity expansion and commissioning aimed to support future growth.
2 more points from Rossari Biotech Ltd's call on order book
Create a free account to keep reading this call
Rossari Biotech Ltd — Quarterly revenue & net profit
Rossari Biotech Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 586 | 498 | +17.7% | 544 | +7.7% |
| Operating profit (EBITDA) | 72 | 66 | +9.1% | 68 | +5.9% |
| Operating margin | 12% | 13% | -1 pp | 12% | 0 pp |
| Profit before tax | 50 | 48 | +4.2% | 46 | +8.7% |
| Net profit (PAT) | 37 | 35 | +5.7% | 34 | +8.8% |
| EPS (₹) | 6.66 | 6.39 | +4.2% | 6.07 | +9.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rossari Biotech's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Gujarat Alkalies (Q2 FY26)
2,136.64 Crores (Page 21). Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q2 FY26 investor presentation — and how it ranks against
- Dynemic Products (Q2 FY26)
Quarterly revenue for Q2 FY 25-26: ₹8,935 lakhs (Page 12, 10, 5) . Key investor presentation takeaways from Dynemic Products's Q2 FY26 investor presentation — a
- Platinum Industr (Q2 FY26)
Q2FY26 Revenue from Operations (Consolidated): INR 983.8 Mn, down 1% YoY from INR 996.4 Mn in Q2FY25. Key investor presentation takeaways from Platinum Industri
- IVP (Q2 FY26)
Revenue from Operations for Q2FY26: ₹146.95 crores . Key investor presentation takeaways from IVP's Q2 FY26 investor presentation — and how it ranks against sec
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rossari Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rossari Biotech Ltd Q2 FY26 results?
Revenue growth in Q2 FY26 was strong at 18% YoY, driven largely by volume increases across all verticals (HPPC, TSC, AHN). Rossari expects steady volume-driven revenue growth with exports rising robustly (36% YoY in Q2), supported by product portfolio expansion and new capacities.
What is Rossari Biotech Ltd share price analysis?
Rossari Biotech Ltd currently shows a neutral. The stock trades at a P/E of 18.5 with a market cap of ₹2,786 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rossari Biotech Ltd planning capital expenditure?
Rs. 97 crore and Rs. 95 crore capex announced last quarter, expected to come on stream in FY27 via 5-6 projects in a phased manner.
Keep Rossari Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
